Accrual to earlier-phase trials included patients with tumor types in which rhIL-2 and anti-PD-(L)1 agents have demonstrated substantial overall survival benefit (i.e., cutaneous melanoma, renal cell carcinoma) and those in which single-agent immune checkpoint therapy approaches have not yielded meaningful response rates (i.e., platinum-resistant ovarian cancer, pancreas adenocarcinoma). Here, CD274 is linked to hereditary clear cell renal cell carcinoma.